Skip to main content
SpringerLink
Log in

Pilot study in humans on the pharmacokinetics and safety of propofol 6% SAZN

  • Published:
Pharmacy World and Science Aims and scope Submit manuscript

Abstract

In a pilot study on the first application of Propofol 6% SAZN in humans, the pharmacokinetics and safety of the new product seem to be similar to those of Propofol 1% SAZN and Diprivan®‐10 after bolus injection. The results will have to be confirmed in a larger clinical study in order to develop Propofol 6% SAZN as an alternative for Diprivan®‐10.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bryson HM, Fulton BR, Faulds D. Propofol. An update of its use in anaesthesia and conscious sedation. Drugs 1995;50:513-59.

    PubMed  Google Scholar 

  2. Fulton B, Sorkin EM. Propofol. An overview of its pharmacology and a review of its clinical efficacy in intensive care sedation. Drugs 1995;50:636-57.

    PubMed  Google Scholar 

  3. Gottardis M, Khünl-Brady KS, Koller W, Sigl G, Hackl JM. Effect of prolonged sedation with propofol on serum triglyceride and cholesterol concentrations. Br J Anaesth 1989;62:393-6.

    PubMed  Google Scholar 

  4. Parke TJ, Stevens JE, Rice ASC, et al. Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports. BMJ 1992;305:613-6.

    PubMed  Google Scholar 

  5. Knibbe CAJ, Koster VS, Deneer VHM, Stuurman RM, Kuks PFM, Lange R. Determination of propofol in low volume samples by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl 1998;706:305-10.

    PubMed  Google Scholar 

  6. Cummings GC, Dixon J, Kay NH, et al. Dose requirements of ICI 35,868 (Propofol, 'Diprivan') in a new formulation for induction of anaesthesia. Anaesthesia 1984;39:1168-71.

    PubMed  Google Scholar 

  7. Dutta S, Matsumoto Y, Ebling WF. Propofol pharmacokinetics and pharmacodynamics assessed from a cremophor EL formulation. J Pharm Sci 1997;86:967-9.

    PubMed  Google Scholar 

  8. Dutta S, Ebling WF. Emulsion formulation reduces propofol dose requirements and enhances safety. Anesthesiology 1997;87:1394-405.

    PubMed  Google Scholar 

  9. Doenicke AW, Roizen MF, Rau J, et al. Pharmacokinetics and pharmacodynamics of propofol in a new solvent. Anesth Analg 1997;85:1399-403.

    PubMed  Google Scholar 

  10. Cox EH, Knibbe CAJ, Koster VS, et al. Influence of different fat emulsion-based intravenous formulations on the pharmacokinetics and pharmacodynamics of propofol. Pharm Res 1998;15:442-8.

    PubMed  Google Scholar 

Download references

Authors
  1. Catherijne A.J. Knibbe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Victorine S. Koster
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Leon P.H.J. Aarts
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Han J.M. Langemeijer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Meindert Danhof
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Knibbe, C.A., Koster, V.S., Aarts, L.P. et al. Pilot study in humans on the pharmacokinetics and safety of propofol 6% SAZN. Pharm World Sci 21, 239–240 (1999). https://doi.org/10.1023/A:1008701004814

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1008701004814

Search

Navigation